Label-free interaction analysis is of increasing importance for scientists in academia, pharma, biotech and diagnostics. Biacore™ systems provide exceptional performance, generating data on the interactions between proteins and other molecules, including small molecule drug candidates. During research, development and manufacture, these data give insights into protein functionality, elucidate disease mechanisms and play a key role in the critical decisions needed for efficient development and production of therapeutics. Biacore systems are used in areas such as drug discovery, antibody characterization, proteomics, immunogenicity, biotherapeutic development and manufacture, and many life science research applications.
“It’s a great honour to receive this award. Biacore SPR technology has been helping investigators understand protein interactions in life sciences since its launch in 1990 and I am very proud to have played a part in its inception,” said Robert Karlsson, Biacore Research and Development, GE Healthcare. Mr Karlsson published the original paper on kinetic analysis of biomolecular interactions using surface plasmon resonance in 1991.
One of the founders of Biacore, Inger Rönnberg‘s initial work focused on applications for label-free surface plasmon resonance detection that resulted in the launch of the first Biacore instrument in 1990. Mrs Rönnberg continues to work as a Project Office Manager, leading the project management team at GE Healthcare’s instrument manufacturing facility in Umea.
Dr. Malmqvist was co-founder of Biacore and was responsible for the introduction and development of the technology during his time at the company. He continues to be an innovator in biomolecular science and business development and is currently chairman of Ridgeview Instruments AB, which recently introduced a new technology (LigandTracer®) for real-time analysis of molecular interactions with cells. Dr. Malmqvist is also Chief Science Officer at Bioventia, a consultancy focused on providing strategic market analysis and business support to new life science companies.
For more information on Biacore systems, visit: www.gelifesciences.com/biacore
ABOUT GE HEALTHCARE:
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
ABOUT GE HEALTHCARE:
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
